{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_198578.2:c.6053C>T",
          "cDNA Change": {
            "transcript": "NM_198578.2",
            "ref": "C",
            "alt": "T",
            "position": "6053"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "G2019S"
        },
        {
          "HGVS": "NM_198578.2:c.6059T>C",
          "cDNA Change": {
            "transcript": "NM_198578.2",
            "ref": "T",
            "alt": "C",
            "position": "6059"
          },
          "Protein Change": {
            "ref": "I",
            "alt": "T",
            "position": "2020"
          },
          "Description in input context": "I2020T"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson’s disease",
    "MONDO": "MONDO:0005006"
  },
  "Experiment Method": [
    {
      "Assay Method": "TR-FRET competitive binding assay",
      "Material used": {
        "Material Source": "Commercially sourced",
        "Material Name": "N-terminal GST-tagged LRRK2 (amino acids 970–2527)",
        "Description": "N-terminal GST-tagged LRRK2 (amino acids 970–2527) wild-type, G2019S, and I2020T were from Invitrogen Corporation."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_198578.2:c.6053C>T",
          "Conclusion": "Sensitive to ATP-competitive inhibitors",
          "Molecular Effect": "Gain-of-function",
          "Result Description": "G2019S has approximately 2-fold lower ATP affinity and is 1.6-fold more sensitive to ATP-competitive kinase inhibitors at 1 mM ATP."
        },
        {
          "Variant": "NM_198578.2:c.6059T>C",
          "Conclusion": "Resistant to ATP-competitive inhibitors",
          "Molecular Effect": "Loss-of-function",
          "Result Description": "I2020T has approximately 9-fold higher ATP affinity and is approximately 10-fold more resistant to ATP-competitive kinase inhibitors at 1 mM ATP."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "All assays were performed using either three or four replicates for each data point."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Duplicate kinase reactions were performed."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly mentioned."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Curve fitting and data analysis were performed with GraphPad Prism software."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Kinase activity assay",
      "Material used": {
        "Material Source": "Commercially sourced",
        "Material Name": "N-terminal GST-tagged LRRK2 (amino acids 970–2527)",
        "Description": "N-terminal GST-tagged LRRK2 (amino acids 970–2527) wild-type, G2019S, and I2020T were from Invitrogen Corporation."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_198578.2:c.6053C>T",
          "Conclusion": "Sensitive to ATP-competitive inhibitors",
          "Molecular Effect": "Gain-of-function",
          "Result Description": "G2019S has approximately 3-fold higher kinase activity and 3-fold higher ATP Km,app."
        },
        {
          "Variant": "NM_198578.2:c.6059T>C",
          "Conclusion": "Resistant to ATP-competitive inhibitors",
          "Molecular Effect": "Loss-of-function",
          "Result Description": "I2020T has approximately 7-fold lower ATP Km,app and 3-fold lower Vmax."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "All assays were performed using either three or four replicates for each data point."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Duplicate kinase reactions were performed."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly mentioned."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Curve fitting and data analysis were performed with GraphPad Prism software."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}